EUVIMEDEUVIMED entdecken
KohortenstudieStudienprotokollOpen Access · CC BY-NC 4.0

Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol

James Hallimond Brindley iD, Kushala Abeysekera, Gill Hood, Stacey Jennings iD, John Moore, Matthew Hickman iD, William Alazawi

BMJ Open · 2023

DOI: 10.1136/bmjopen-2022-066493 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift BMJ Open, 2023. Verfasst von James Hallimond Brindley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Barts Liver Centre, Queen Mary University of London, London, UK h.brindley@qmul.ac.uk. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide affecting 20%–25% in the USA and Europe with a 60%–80% lifetime prevalence for people with type 2 diabetes (T2D). Fibrosis has repeatedly been demonstrated to be the major determinant of liver disease morbidity and mortality and there is currently no routine screening for liver fibrosis in at-risk T2D population. Methods and analysis This 12-month prospective cohort study of automated fibrosis testing uses the fibrosis-4 score (FIB-4) in patients with T2D linked to the investigation of hospital-based versus community-based second-tier transient elastography (TE) testing. We plan to include >5000 participants across 10 General Practitioner (GP) practices in East London and Bristol. This will determine the rate of undiagnosed significant liver fibrosis in a T2D population, the feasibility of two-tier liver fibrosis screening using FIB-4 at the diabetes annual review and subsequent TE delivered either in the community or secondary care settings. This will include an intention-to-treat analysis for all those invited to attend for diabetes annual review. A qualitative substudy regarding the acceptability of the fibrosis screening pathway will comprise semistructured interviews/focus groups with primary care staff (GPs and practice nurses), and patients taking part in the wider study. Ethics and dissemination This study received a favourable opinion from the Cambridge East research ethics committee. The results of this study will be disseminated in peer-reviewed scientific journals, conference presentations and local diabetes lay panel meetings. Trial registration number ISRCTN14585543 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseHumansFeasibility StudiesFibrosisLiver CirrhosisPrimary Health CareProspective Studies

Stichwörter der Autor:innen

general diabeteshepatologyprimary careprotocols & guidelines

Autor:innen und Institutionen

  • Barts Liver Centre, Queen Mary University of London, London, UK h.brindley@qmul.ac.uk.
  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Barts Liver Centre, Queen Mary University of London, London, UK.
  • Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • Bristol Population Health Science Institute, University of Bristol, Bristol, UK.

ORCID-Profile: James Hallimond Brindley, Stacey Jennings, Matthew Hickman

Förderung

  • Gilead Sciences

Zitieren

APA

Brindley, J. H., Abeysekera, K., Hood, G., Jennings, S., Moore, J., Hickman, M., & Alazawi, W. (2023). Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2022-066493

Vancouver

Brindley JH, Abeysekera K, Hood G, Jennings S, Moore J, Hickman M, et al. Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol. BMJ Open. 2023. doi:10.1136/bmjopen-2022-066493

BibTeX
@article{Brindley2023,
  author = {Brindley, James Hallimond and Abeysekera, Kushala and Hood, Gill and Jennings, Stacey and Moore, John and Hickman, Matthew and Alazawi, William},
  title = {Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol},
  journal = {BMJ Open},
  year = {2023},
  doi = {10.1136/bmjopen-2022-066493}
}
Kostenlos starten →